Naomi Fei, MD
Medical Oncology · Iowa City, IANPI 1760878755
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), grants and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 31.5% of the total. Reporting peaked in 2019 at $743 and has fallen 76.5% since, to $175 in 2025. That places this record below the midpoint for medical oncology clinicians in IA, where the typical reported total is $879.
Across 9 payments — averaging $128.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$365
- Incyte Corporation$303
- Exelixis Inc.$175
- AstraZeneca$129
- Seagen Inc.$95
- Takeda Pharmaceuticals U.S.A., Inc.$75
- plus $15 from 1 others
Across 2 payments — averaging $81,916 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$118K
- AstraZeneca$46K
What the payments were for
- Grants$36532%
- Food & beverage$58450%
- Education$20918%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $365 |
| Incyte Corporation | 3 | $303 |
| Exelixis Inc. | 1 | $175 |
| AstraZeneca | 1 | $129 |
| Seagen Inc. | 1 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $75 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,158 in reported general payments places this provider in the 50th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 74 | $114,665 |
| EliquisApixaban | 60 | $36,174 |
| Dexamethasone | 311 | $981 |
| Prochlorperazine Maleate | 78 | $789 |
| Ondansetron Hcl | 88 | $748 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 20 | $448 |
| LoperamideLoperamide Hcl | 24 | $431 |
| Potassium Chloride | 36 | $306 |
| Tramadol Hcl | 31 | $224 |
| Olanzapine | 18 | $188 |
| Omeprazole | 13 | $183 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $171 |
| Oxycodone Hcl | 27 | $163 |
| Nystatin | 13 | $161 |
| Pantoprazole Sodium | 22 | $156 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Iowa City
- Jun ZhangIowa City$377K
- John RiethIowa City$11K
- Mark BurkardIowa City$10K
- Fernando Maciel BarbosaIowa City$3K
- Gustavo Fernandes Godoy AlmeidaIowa City$2K
- Margaret ByrneIowa City$1K
- Saima SharifIowa City$122
- Susan RoederIowa City$47
- Margarida SilvermanIowa City$0
- Tara GraffClive$702K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.